Stockscreener 앱 받기
0.64
4.55%
-0.0305
전일 마감가:
$0.6705
열려 있는:
$0.71
하루 거래량:
14.25M
Relative Volume:
1.14
시가총액:
$101.84M
수익:
$10.00M
순이익/손실:
$-29.47M
주가수익비율:
-3.20
EPS:
-0.2
순현금흐름:
$-21.55M
1주 성능:
+29.45%
1개월 성능:
-69.52%
6개월 성능:
-63.43%
1년 성능:
-77.93%
1일 변동 폭
$0.6033
$0.71
1주일 범위
$0.51
$0.78
52주 변동 폭
$0.20
$3.255
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
명칭
Mereo Biopharma Group Plc Adr
전화
4403330237300
주소
ONE CAVENDISH PLACE, LONDON
MREO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.64 | 106.70M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-30 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2023-10-13 | 재개 | BTIG Research | Buy |
| 2022-08-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Needham | Buy |
모두보기
Mereo Biopharma Group Plc Adr 주식(MREO)의 최신 뉴스
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - Chartmill
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Silver Tumbles 8%; Society Pass Shares Spike Higher - Sahm
Dow Falls Over 100 Points; US Pending Home Sales Rise In November - Sahm
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta - Investing News Network
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows - Sahm
Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - Defense World
Mereo BioPharma Group’s (MREO) “Buy” Rating Reaffirmed at BTIG Research - Defense World
BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data - Investing.com UK
683 Capital Management LLC Decreases Stock Holdings in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat
Investors Buy High Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat
It makes sense and dollars to buy Mereo Biopharma Group Plc ADR (MREO) stock - setenews.com
Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com UK
Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch - Yahoo Finance
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc (MREO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Equities Analysts Issue Forecasts for MREO FY2025 Earnings - Defense World
A better buy-in window may exist right now for Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street analysts’ outlook for Mereo Biopharma Group Plc ADR (MREO) - Setenews
FY2025 EPS Forecast for Mereo BioPharma Group Cut by Analyst - Defense World
Leerink Partnrs Has Negative Forecast for MREO Q4 Earnings - MarketBeat
Leerink Partnrs Issues Negative Forecast for MREO Earnings - Defense World
A new trading data show Mereo Biopharma Group Plc ADR (MREO) is showing positive returns. - setenews.com
Mereo Biopharma Group Plc Adr (MREO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):